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new directions in drug design are the contributions by Dr. Sartorelli and Dr. R.H.
Abeles. Dr. Sartorelli's innovative approach to the development of bioreductive
alkylating agents as chemotherapeutic agents for hypoxic tumor cell populations and
Dr. Abeles's elegant mechanistic work on the design ofspecific "suicide inhibitors" of
important enzymes exemplify the new wave of medicinal chemistry which is rapidly
taking hold in enlightened scientific circles. Part II, "Antibiotics," deals virtually
exclusively with DNA-drug interactions. Dr. H.M. Sorbell sets down the biophysical
framework with his important work on drug intercalation, followed by Drs. S.T.
Crooke, I.H. Goldberg, and F. Hutchinson, who discuss their interestingfindings on
the molecular pharmacology of the DNA-interacting anthracyclines, neocarzinos-
tatin, and bleomycins, respectively.
Parts III and IV deal with antimetabolites. In Part III the subject of"Nucleoside
Analogs" is approached from the question of transport by Dr. A.R.P. Paterson, the
design of inhibitors of purine nucleoside phosphorylases by Dr. R.E. Parks, Jr., and
of S-adenosyl-methionine dependent enzymes by Dr. J.K. Coward. Mechanistic
work on the clinically important 5-fluorouracil is thoroughly discussed by Drs. F.
Maley and D.V. Santi. "Folate Analogs" in Part IV are discussed in terms of X-ray
binding studies to dihydrofolate reductase by Dr. R.L. Blakley, transport by Drs.
F.M. Huennekens and F.M. Sirotnack, and cellular resistance via gene amplification,
an exciting recent discovery, by Dr. Bertino. Part V, entitled "Radiation Sensitizers,"
contains good discussions of the problem of hypoxic cells in radiotherapy by Dr.
G.E. Adams and the considerations in the design of new hypoxic cells sensitizers by
Dr. J.D. Chapman.
"Membrane Targets" is the subject of Part VI. Dr. D.F.H. Wallach discusses
general considerations of plasma membranes in chemotherapy while Dr. J.C. Biedler
examines altered membrane glycoconjugates in Chinese hamster cells with acquired
drug resistance. One of the more intriguing papers by Dr. S.B. Horwitz presented
some fine studies on steganacin and taxol which are inhibitors oftubulin polymeriza-
tion to microtubules, an important constituent ofthe cytoskeleton ofeukaryotic cells.
Part VII, "Angiogenesis-Metastasis-Anticarcinogenesis-Differentiation" handles
some of the more esoteric aspects of chemotherapy. The studies on angiogenesis
inhibitors by Dr. J. Folkman, retinoids by Drs. G.L. Nicolson and M.B. Sporn, and
on differentiation by Drs. R.C. Gallo and L. Sachs are fascinating reading though
their relationships to the title of this book may seem abstruse.
Overall, the editors deserve much praise for organizing an impressive symposium
and for producing this informative volume. For those who attended the proceedings
this book will satisfy the frustration of the short presentations. For the cancer
research community in general it will be a timely collection of progress reports from
many of the leaders in diverse areas of basic cancer chemotherapy.
JOHN W. KOZARICH
Department ofPharmacology and Developmental Therapeutics Program
Comprehensive Cancer Center
Yale University School ofMedicine
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The explosive advances in molecular biology are nowhere more apparent than in
the field of pituitary hormones. Within a handful of years, a- and p-melanotropin
(MSH), considered the standard pigment-inducing hormones, have been demon-strated in mammalian systems to be physiologically unimportant metabolites of
corticotropin (ACTH) and lipotropin (LPH), respectively. LPH is also the precurser
of endorphin, an endogenous analgesic peptide acting at morphine receptor sites in
the brain and exhibiting potent behavioral-affecting activity as well. Microquantities
of pituitary extracts can now be rapidly resolved into pure components by high-
pressure liquid chromatography and screened for biologic activity by radioimmu-
noassay. The DNA coding for the prohormone of the MSH-ACTH-LPH group of
peptides has been prepared bycloning and its sequence determined. This provides the
amino acid sequence of the prohormone "pro-opiocortin," a peptide of molecular
weight 26,000 which contains the sequence Tyr-X-Met-X-His-Phe-Arg-Trp-X three
times within its linear structure. From the sequence of pro-opiocortin a third
melanotropin "'Y-MSH," was postulated and shortly thereafter isolated.
These studies and many others were presented at a Ciba Foundation Symposium,
June 1980: Peptides ofthe Pars Intermedia. Participants included many ofthe active
contributors to the field. Subjects ranged from peptide chemistry and structure-
activity speculations through cytochemistry and neurophysiology to intrauterine
growth and adaptive behavior of mammals. The book will therefore be of interest to
a wide range of investigators. Congratulations to the Ciba Foundation, the editors,
organizers, and participants for an excellent symposium and to Pitman Medical for a
most timely and useful proceedings manual.
SAUL LANDE
Department ofDermatology
Yale University School of Medicine
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